ArticleOncology letters2021
EGFR and ERK activation resists flavonoid quercetin-induced anticancer activities in human cervical cancer cells
Article in Oncology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Quercetin ameliorates HIV-1 gp120 protein-induced intestinal barrier dysfunction by inhibiting the activation of the ERK1/2 signaling pathway in a Caco-2 cell model.AIDS research and therapy · 2026Article
- A Narrative Review of Quercetin's Role as a Bioactive Compound in Female Reproductive Disorders.Nutrients · 2025Review
- Incredible use of plant-derived bioactives as anticancer agents.RSC advances · 2025Review
- Pharmacodynamics and safety in relation to dose and response of plant flavonoids in treatment of cancers.Inflammopharmacology · 2025Review
- Gasdermin D regulates the activation of EGFR in colorectal cancer.Journal of translational medicine · 2024Article
- Flavonoids: Antioxidant Powerhouses and Their Role in Nanomedicine.Antioxidants (Basel, Switzerland) · 2024Review
- Investigation of the potential effects of estrogen receptor modulators on immune checkpoint molecules.Scientific reports · 2024Article
- RACK1 promotes the occurrence and progression of cervical carcinoma.Journal of clinical laboratory analysis · 2024Article
- Quercetin in Oncology: A Phytochemical with Immense Therapeutic Potential.Current drug targets · 2024Review
- A comparative analysis of phyto-components on EGFR binding, viability, and migration in HPV positive ME180 and HPV negative C33A cervical cancer cells.Medical oncology (Northwood, London, England) · 2023Article
- Targeting PI3K/Akt signaling in prostate cancer therapy.Journal of cell communication and signaling · 2023Review
- Article
- Recent Progress in Nanotechnology Improving the Therapeutic Potential of Polyphenols for Cancer.Nutrients · 2023Review
- Potential ofMolecules (Basel, Switzerland) · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present study, due to the complex and numerous targets of Sarcandrae Herb (also known as Zhong Jie Feng), network pharmacology was performed to analyze its therapeutic effect on 2 cervical cancer cell lines, which could assist with the development of novel therapies. The results suggested that the natural flavonoid quercetin (Que), the effective antitumor ingredient in SH, which is widely present in a variety of plants, may depend on the target, EGFR. Previous studies have shown that EGFR serves a crucial role in the occurrence and development of cervical cancer, but its downstream molecules and regulatory mechanisms remain unknown. The anti-cervical cancer cell properties of Que, which are present in ubiquitous plants, were examined
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.